Division of Infectious Disease, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Department of Laboratory Medicine, University of California, San Francisco, California, USA.
Am J Transplant. 2020 Nov;20(11):3225-3233. doi: 10.1111/ajt.16079. Epub 2020 Jul 17.
The coronavirus disease 2019 (COVID-19) pandemic caused by SARS coronavirus 2 (SARS-CoV-2) has caused significant morbidity and mortality for patients and stressed healthcare systems worldwide. The clinical features, disease course, and serologic response of COVID-19 among immunosuppressed patients such as solid organ transplant (SOT) recipients, who are at presumed risk for more severe disease, are not well characterized. We describe our institutional experience with COVID-19 among 10 SOT patients, including the clinical presentation, treatment modalities, and outcomes of 7 renal transplant recipients, 1 liver transplant recipient, 1 heart transplant recipient, and 1 lung transplant recipient. In addition, we report the serologic response in SOT recipients, documenting a positive IgG response in all 7 hospitalized patients. We also review the existing literature on COVID-19 in SOT recipients to consolidate the current knowledge on COVID-19 in the SOT population for the transplant community.
由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起的 2019 年冠状病毒病(COVID-19)大流行,给患者带来了重大的发病率和死亡率,并给全球的医疗保健系统带来了压力。免疫抑制患者(如实体器官移植(SOT)受者)的 COVID-19 的临床特征、疾病过程和血清学反应特征尚不清楚,这些患者被认为有更严重疾病的风险。我们描述了我们机构在 10 名 SOT 患者中 COVID-19 的经验,包括 7 名肾移植受者、1 名肝移植受者、1 名心脏移植受者和 1 名肺移植受者的临床表现、治疗方式和结果。此外,我们报告了 SOT 受者的血清学反应,记录了所有 7 名住院患者的 IgG 阳性反应。我们还回顾了 SOT 受者 COVID-19 的现有文献,以整合目前关于 SOT 人群 COVID-19 的知识,供移植界参考。